Medicine and Dentistry
Alagille Syndrome
19%
Alanine Aminotransferase
24%
Alkaline Phosphatase
24%
Antiviral Therapy
13%
Aspartate Aminotransferase
15%
Autoimmune Hepatitis
19%
Bile Acid
13%
Bilirubin
12%
Cholangiocarcinoma
29%
Chronic Hepatitis B
93%
Clinical Trial
30%
Cohort Analysis
18%
Colorectal Carcinoma
19%
Congenital Diaphragm Hernia
19%
Decompensated Liver Cirrhosis
16%
Diabetes Mellitus
11%
Disease Course
11%
Diseases
17%
Event Free Survival
29%
Fibrosis
25%
Graft Failure
17%
Graft Survival
13%
Hazard Ratio
62%
Hepatectomy
21%
Hepatitis B
21%
Hepatitis B Antigen
39%
Hepatitis B Virus
36%
Hepatitis B(e) Antigen
38%
Hepatitis C Virus
19%
Hepatocellular Carcinoma
57%
Infection
15%
Liver Cirrhosis
37%
Liver Disease
12%
Liver Transplantation
72%
Meta-Analysis
19%
Obeticholic Acid
29%
Overall Survival
23%
Peginterferon
29%
Placebo
26%
Platelet
11%
Prevalence
14%
Primary Biliary Cirrhosis
90%
Prognostic Factor
11%
Randomized Controlled Trial
14%
Recurrent Disease
33%
Retrospective Cohort Study
20%
Systematic Review
39%
Transaminase
12%
Treatment Response
12%
Ursodeoxycholic Acid
52%
Pharmacology, Toxicology and Pharmaceutical Science
Alagille Syndrome
19%
Alanine Aminotransferase
15%
Alkaline Phosphatase
23%
Alpha Interferon
13%
Aminotransferase
12%
Aspartate Aminotransferase
15%
Autoimmune Hepatitis
19%
Beclometasone
9%
Bile Acid
13%
Bilirubin
11%
Breast Cancer
9%
Chronic Hepatitis B
83%
Chronic Hepatitis C
19%
Clinical Trial
19%
Cohort Study
36%
Colorectal Carcinoma
19%
Diabetes Mellitus
11%
Disease Course
11%
Diseases
28%
Entecavir
19%
Event Free Survival
29%
Fibrosis
22%
Genetic Risk
9%
Hepatitis B
13%
Hepatitis B Antigen
51%
Hepatitis B Core Antigen
9%
Hepatitis B Virus
21%
Hepatitis B(e) Antigen
57%
Hepatitis C
12%
Hepatitis C Virus
25%
HIV
22%
Immunogenicity
19%
Infection
28%
Interferon
22%
Liver Cell Carcinoma
12%
Liver Cirrhosis
27%
Liver Disease
28%
Liver Fibrosis
11%
Maralixibat
19%
Obeticholic Acid
32%
Overall Survival
14%
Peginterferon
49%
Placebo
29%
Polyethylene Glycol
11%
Prevalence
32%
Primary Biliary Cirrhosis
100%
Prothrombin
9%
Ursodeoxycholic Acid
46%
Vaccine Development
9%
Virus Vaccine
9%
Immunology and Microbiology
Agonist
5%
Alanine
20%
Alpha Fetoprotein
9%
Autoimmune Hepatitis
19%
Autoimmune Liver Disease
8%
Booster Dose
19%
COVID-19
19%
Enterohepatic Circulation
9%
Event Free Survival
9%
HBcAg
9%
HBsAg
28%
HBV DNA
14%
Hepatitis A
9%
Hepatitis B
48%
Hepatitis B Antigen
28%
Hepatitis B Core Antibody
10%
Hepatitis B Virus
8%
Hepatitis B(e) Antigen
25%
Hepatitis C
9%
Hepatitis C Virus
19%
Human Immunodeficiency Virus
25%
Immunogenicity
19%
Interferon Type I
20%
Liver Transplantation
21%
Overall Survival
16%
Pegylated Interferon
19%
Prednisone
5%
Prevalence
19%
Primary Biliary Cirrhosis
30%
Survival Rate
6%
Tenofovir
5%
TLR7
5%
Toll-Like Receptor
9%
Viral Disease
9%
Viral Load
8%
Virus Vaccine
9%